Bridgebio Oncology Therapeutics Says BBO-8520 Monotherapy Shows 63% ORR, 100% DCR In 2L+ KRASG12C NSCLC; BBO-11818 And BBO-10203 Monotherapy Data Update Expected In Q4 2026; Expanded BBO-8520 Plus Pembrolizumab Dataset Expected In Mid-2027; BBO-11818 And BBO-10203 Combination Data In CRC And PDAC Expected Mid-2027
BridgeBio's cancer medicine BBO-8520 helped a big group of patients with a tough lung cancer type, which is a good sign for the company's work. When a medicine works well in early tests, it hints the company might be on the right track, but there's still a long way to go before we know if it will really help patients in the real world.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.